A photo showing the logo of the Swiss pharmaceutical giant Roche in Basel.
Sébastien Bozon | AFP | Getty images
Swiss pharmaceutical giant Rock Tuesday said That he would invest $ 50 billion in the United States over the next five years, in a context of concerns about the impact of possible rates of the White House possible on pharmaceuticals from abroad.
The investment will create more than 12,000 jobs, said Roche – 1,000 with the company and the rest to support the new American manufacturing capacities. The company has said that it already employs more than 25,000 people in America.
Roche shares were more than 1.1% down at 8:39 a.m. in London.
The pharmaceutical giant will inject money to create new advanced research and development sites (R&D), while strengthening and widening manufacturing facilities in Indiana, Pennsylvania, Massachusetts and California. A new R&D site in Massachusetts will be used for AI research and will act as research center on cardiovascular, renal and metabolistic treatments.
The financing package will also be used to build a new 900,000 square feet manufacturing center in an unknown location to support the “expansion portfolio of rock loss drugs of new generation”.
Once new manufacturing capacity investments are completed, Roche said that it would export more drugs from the United States that it did not matter.
Pharmaceutical companies rushed to strengthen their American presence in the middle threats President Donald Trump to end the exemption from the import prices industry.
“We will quickly announce a major price on pharmaceutical products,” he said earlier this month.
Roche’s investment follows similar movements from the main competitors. Earlier this month, Novartis in Switzerland announcement Plans to invest $ 23 billion to build and extend 10 American installations, in a decision which, according to him, would create more than 4,000 jobs.
British pharmaceutical giant Astrazeneca, last, said that he would invest $ 2.5 billion in the creation of a Beijing center. However, the CEO of the company Pascal Soriot told CNBC at the time that Astrazeneca remained “very attached to the United States”, where he had two “very large” research and development centers.
Roche CEO, Thomas Schinecker, said in a statement on Tuesday that the new $ 50 billion investment in the company had demonstrated its “long-standing commitment to research, development and manufacturing in the United States”.
“We are proud of our 110-year inheritance in the United States, which was a key engine for jobs, innovation and the creation of intellectual property in the United States, both in our pharmaceutical and diagnostic divisions,” he said. “Our $ 50 billion investments over the next five years will launch the basics of our next era of innovation and growth, benefiting patients in the United States and worldwide.”
